GLPwatch
Intravenous Exenatide in Patients With Acute Brain Injury
NCT02058940 · Completed
Last updated 2026-05-28This clinical trial is testing whether giving exenatide through an IV to critically ill patients with acute brain injuries is feasible.
Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design open-label (no blinding) treatment study
Participants 8 people
Who can join Ages 18+ · all sexes
Timeline Started 2015-08 · est. completion 2017-08
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT02058940 ↗
Description as written by the study sponsor.
The purpose of this study is to assess the feasibility of exenatide infusion for the treatment of high blood sugars following acute brain injury.
Treatments tested
- Exenatide Drug
50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
| Main thing measured | Percentage of Critically Ill Patients With Acute Brain Injury Achieving Pre-specified Feasibility Criteria |
|---|---|
| Sponsor | University of North Carolina, Chapel Hill |
| Conditions studied | Brain Injuries |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02058940 ↗